Conflict of interest

From Cancer Guidelines Wiki

Competing interest declarations and management

Working Party Members were asked to declare in writing, any interests relevant to the guideline development, prior to commencement. Members were asked to update their information if they became aware of any changes to their interests.

All declarations were added to a register of interests as listed below. The register was made available to the Working Party throughout the development of the guideline, allowing members to take any potential conflicts of interest into consideration during discussions, decision making and formulation of recommendations.

If Working Party Members were identified as having a significant real or perceived conflict of interest, the Chair could decide that the member either leave the discussion whilst the specific area they were conflicted in was discussed or the member could remain present but not participate in the discussion, or decision making on the specific area where they were conflicted. There were no instances where this occurred during the development of this guideline.


Working party member Competing interest declaration
Assoc Prof Chris Hemmings No competing interest to declare.
Professor David Thomas FRACP, PhD No competing interests to declare with respect to the matters contained in these guidelines.

Received sponsorship to attend meetings and research support from Amgen, Pfizer and Novartis.

Associate Professor Gelareh Farshid No competing interest to declare.
Dr Grant Pang To be confirmed
Dr Jayesh Desai Shares: NIL

Research Support: Novartis, Pfizer, Roche, GSK, Plexxikon

Consultancy: Novartis, Pfizer, GSK, Merck Serono, Sanofi, Bionomics, Circadian

Dr Julie Chu No competing interest to declare.
Dr Kirsten Gormly No competing interest to declare.
Dr Marcus Foo FRANZCR No competing interest to declare.
Professor Martin Tattersall SCD, MD FRACP No direct pecuniary interest to declare.

Attended an investigator meeting in Seoul and Los Angeles related to trials of new drugs in chondrosarcoma and soft tissue sarcoma. The flight and accommodation was covered by the sponsoring company.

Dr Paul Stalley TBC
Professor Peter Choong FRACS, FAOrth A, MBBS MD Prosthetic design team, Zimmer Corporation, USA for which travel and accommodation costs and past royalties have been paid.

Instrument design team, Johnson & Johnson, USA for which travel and accommodation costs, and per diem have been paid. ARC Linkage grant with industry partner, Johnson & Johnson

Dr Raghu Gowda MSc MD MRCP(UK) FRCR(UK) FRANZCR No competing interest to declare.
Dr Richard Boyle FRACS FA(Orth)A No competing interest to declare.
Dr Roger Woods MBBS, FRACS No competing interest to declare.
Associate Professor Sam Ngan, MBBS, FRCSE, FRANZCR No competing interest to declare.
Dr Sarat Chander FRANZCR No competing interest to declare.
Dr Steve Chryssidis No competing interest to declare.
Associate Professor Susan Neuhaus Board of Directors, Cancer Council South Australia (CCSA)

Board of Directors, Australasian Sarcoma Study Group (ASSG)

Dr Warren Hargreaves No competing interests to declare